Researchers discovered that degeneration in the locus coeruleus, alongside the hypothalamus, contributes to sleepiness and muscle weakness in narcolepsy type 1.
RT’s Three Key Takeaways:
- Dual Brain Region Involvement: Research indicates that narcolepsy with cataplexy involves the degeneration of neurons in both the hypothalamus and the locus coeruleus.
- Norepinephrine Neuron Loss: Study participants with narcolepsy had an average of 46% fewer norepinephrine-producing neurons in the locus coeruleus, a region critical for regulating wakefulness and muscle tone.
- Clinical Diagnostic Accuracy: The discovery of a second affected brain region may explain why up to 30% of narcolepsy patients maintain normal hypocretin levels in their cerebrospinal fluid.
UCLA healthcare researchers identified a second brain region involved in the most severe form of narcolepsy, suggesting the condition is caused by neuronal degeneration in two distinct areas rather than one, according to a study published in Nature Communications.
For 25 years, the medical community attributed narcolepsy with cataplexy primarily to the loss of hypocretin neurons in the hypothalamus. These neurons produce a chemical messenger that regulates wakefulness. However, the new findings show significant degeneration in the locus coeruleus, a brainstem region that produces norepinephrine, a neurotransmitter involved in arousal and muscle tone regulation.
“The locus coeruleus has both upward connections that contribute to wakefulness and downward connections that help maintain muscle tone,” said Thomas Thannickal, associate researcher at the David Geffen School of Medicine at UCLA. “That makes it a compelling candidate for explaining both of the defining symptoms of narcolepsy of sleepiness and cataplexy in a way that the neuronal degeneration in the hypothalamus alone does not fully account for.”
Impact on Norepinephrine Neurons
The research team analyzed postmortem brain tissue from 11 individuals diagnosed with narcolepsy with cataplexy and five neurologically healthy controls. Every narcolepsy patient in the study exhibited a substantial loss of neurons in the locus coeruleus. On average, these patients had 46% fewer norepinephrine-producing neurons compared to the control group, with individual losses ranging from 28% to 66%.
The study also found that the surviving neurons in the locus coeruleus were approximately 18% larger than normal. Researchers suggested this enlargement indicates the remaining cells are working harder to compensate for the loss of neighboring neurons.
Additionally, the team observed signs of neuroinflammation. Microglial cells, which serve as the brain’s immune cells, were more than twice as numerous and significantly larger in narcolepsy patients than in the controls. This pattern suggests an immune-mediated process is driving the cell loss.
Differentiating Human Narcolepsy
To determine if the loss of locus coeruleus neurons was a direct result of hypocretin loss, researchers examined mouse and dog models of narcolepsy. None of the animal models showed a reduction in locus coeruleus neurons, indicating that brainstem damage is a distinct feature of the human disease rather than a downstream effect of hypothalamus damage.
The findings provide a potential explanation for a long-standing diagnostic puzzle. Between 15% and 30% of patients who meet the clinical criteria for narcolepsy with cataplexy have normal hypocretin levels. The involvement of the locus coeruleus may account for these cases.
The research also aligns with the efficacy of current treatments. Medications that increase norepinephrine activity, such as solriamfetol and reboxetine, provide symptom relief for many patients, which is consistent with the role of the locus coeruleus in the disease.
“This doesn’t overturn what we know about hypocretin and narcolepsy,” said Jerome Siegel, professor-in-residence of psychiatry at the David Geffen School of Medicine at UCLA. “but it does suggest we’ve been looking at only part of the picture. Understanding the full scope of the neurological changes in narcolepsy patients is essential if we want to develop more targeted therapies.”
